About the Company

Metropolis Healthcare Limited is a leading diagnostics chain built on over 43 years of scientific excellence. Founded in 1981 when Dr. Sushil Shah established Mumbai’s first referral lab, the Company has evolved into one of India’s most respected diagnostic networks, operating 210 clinical labs with a service network of 4,500+ and 31 ISO:15189 accredited labs (27 NABL-accredited in India and 4 accredited by KENAS in Kenya), including 1 CAP-accredited lab . Metropolis today serves patients across 750+ towns in 28 states and 7 Union Territories, with a strong presence in Africa (company-managed operations in Kenya, Uganda, Ghana, Zambia and Tanzania) and international B2B clients in 12 markets spanning Abu Dhabi, Bangladesh, Congo, Dubai, Maldives, Mauritius, Nepal, Nigeria, Sri Lanka, Uzbekistan, Vietnam and Zimbabwe  . The Company’s offering spans routine and specialised pathology, advanced genetic and molecular diagnostics, preventive healthcare, home collection, hospital lab management and clinical research, with over 3,000 advanced tests and curated panels  . Metropolis has 14 subsidiaries, including entities in India and overseas, as disclosed in the consolidated statements .

Key milestones include: Clinical Research Services (1992); first major acquisition (Sudharma, 2003); capital infusion from ICICI Ventures and acquisition of Golwilkar Metropolis, Pune (2006); strategic investment by Warburg Pincus (2010); listing on Indian stock exchanges and first PPP with NACO (2019–2020); and the acquisition of Hitech Diagnostics to deepen Southern Indian presence (2021). In 2023, Metropolis became the first diagnostics chain to be certified as a Great Place to Work  .

Business Segments

– B2C (Direct-to-consumer): 55 Per cent.

– B2B (Partnerships with standalone labs, hospital chains, and diagnostic networks): 36 Per cent.

– Institutional (Corporate clients, government bodies, and hospital lab management services): 9 Per cent.

Contribution as of FY25 as disclosed in the report’s “Key Business Segments” section .

Key Management

– Ameera Shah – Executive Chairperson and Whole-time Director

– Surendran Chemmenkotil – Chief Executive Officer

– Sameer Patel – Chief Financial Officer

– Dr. Kirti Kazi – Chief Scientific & Innovation Officer and Group Head CSR

– Diya Suri – Chief People Officer

– Mohan Menon – Chief Marketing Officer

– Pinakin Shah – Chief Information Officer

– Kamlesh Kulkarni – Head – Legal & Secretarial

Latest Updates

– Strategic expansion: Acquired Core Diagnostics (Delhi NCR) in FY25 to enhance oncology capabilities; in Q1 FY26, completed acquisitions of Scientific Pathology (Agra, Uttar Pradesh) and Dr Ahujas’ Pathology and Imaging Centre (Dehradun, Uttarakhand) to deepen B2C presence .

– New vertical: Entered Primary Healthcare with a dedicated vertical launched during the year .

– Brand refresh and partnerships: Unveiled a refreshed brand identity; launched Metlink, a Channel Partner Engagement Programme to strengthen the partner ecosystem  .

– Scientific and digital innovation: Introduced 60+ new tests; launched India’s first Human Papillomavirus DNA self‑sampling kit for cervical cancer screening; deployed AI‑powered prostate biopsy testing and AI‑assisted karyotyping; rolled out a TB algorithm nationwide; expanded genomics; established MiLES (Metropolis Institute of Laboratory Education and Skilling); and launched an AI-powered Recommendation Engine for personalised test selection .

– Governance and leadership: Dr. Sushil Shah became Chairman Emeritus and Non‑Executive Director; Ameera Shah was re‑designated as Chairperson & Whole‑time Director; Dr. Aparna Rajadhyaksha joined as Non‑Executive Non‑Independent Director; Purvi Sheth joined as Independent Director; and, subsequent to year‑end, the Board approved appointing Surendran Chemmenkotil as Managing Director from June 01, 2025, and re‑appointing Ameera Shah for five years from March 18, 2026 .

– Capital actions: Issued equity shares pursuant to RSU exercises and a preferential allotment for consideration other than cash (swap of shares) .

– Recognitions: Diagnostic Chain of the Year (Gold) at FE Healthcare Excellence Awards 2024; multiple marketing and workplace accolades; and leadership honours for Ameera Shah in 2024–2025 .